Chemical Name |
RWJ-67657 |
CAS Number |
215303-72-3 |
MDL Number |
MFCD11840606 |
Molecular Formula |
C27H24FN3O |
Molecular Weight |
425.50 |
Synonyms |
JNJ 3026582 |
Introduction of 215303-72-3 :
RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity[1]. In Vitro: RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B, with an IC50 value of 13 nM[2].
RWJ67657 (10 μM; 24 hours) decreases colony formation in MCF-7 cells[3]. In Vivo: RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration[2].
RWJ-67657 (50 mg/kg; administered orally; once per day for 7 consecutive days) displays a potent anti-inflammatory effect. By both improving the functioning of endothelial progenitor cells (EPCs) and reducing inflammation, EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke[4].
Purity |
NLT 98% |
Storage |
at 20ºC 2 years |
*The above information is for reference only.